Literature DB >> 30867373

Preoperative evaluation of the degree of liver fibrosis based on matter-element analysis using serological indicators in patients with hepatocellular carcinoma.

Wei Liu1, Xiaosong Li1, Weihong Zheng2, Rucheng Yao1, Jun Zheng1.   

Abstract

Evaluation of the degree of liver fibrosis is an important basis for the clinical diagnosis and treatment of patients with hepatocellular carcinoma (HCC). It is meaningful to make a preoperative evaluation with non-invasive methods. In the current study, 12 commonly used preoperative serological indicators from 161 HCC patients with different degree of liver fibrosis were collected retrospectively, and 8 of the indicators (ALB, PA, TBil, INR, AST, GGT, ALP, and PT) were ultimately used in matter-element analysis to create a formula. The relationship between those results and the histological sub-classification of the Laennec liver fibrosis scoring system was analyzed. The calculated value of R from this formula will indicate the differing degree of liver fibrosis in a patient: i) the value of 0.802 ≤ R < 1 indicates the early stage of liver cirrhosis, which corresponds to Laennec stages 0-3; ii) the value of 0.752 ≤ R < 0.802 indicates the mild stage of liver cirrhosis, which corresponds to Laennec stage 4A; iii) the value of 0.698 ≤ R < 0.752 indicates the moderate stage of liver cirrhosis, which corresponds to Laennec stage 4B; and iv) the value of 0.444 ≤ R < 0.698 indicates the severe stage of liver cirrhosis, which corresponds to Laennec stage 4C. The hope is that this formula for preoperative evaluation of the degree of liver fibrosis using non-invasive methods would be useful in the clinical diagnosis and treatment of patients with HCC in the future.

Entities:  

Keywords:  Laennec system; Liver cirrhosis; matter-element analysis

Mesh:

Substances:

Year:  2019        PMID: 30867373     DOI: 10.5582/bst.2018.01311

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  7 in total

Review 1.  Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Wen Wen; Yong Zhang; Hua Zhang; Yingshuang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-30       Impact factor: 4.553

2.  Study on correlation between coagulation indexes and disease progression in patients with cirrhosis.

Authors:  Jinlan Peng; Guilin He; Huan Chen; Xiaoqin Kuang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  hsa_circ_0004018 suppresses the progression of liver fibrosis through regulating the hsa-miR-660-3p/TEP1 axis.

Authors:  Shan Li; Fangmin Song; Xu Lei; Jingtao Li; Fang Li; Huabing Tan
Journal:  Aging (Albany NY)       Date:  2020-06-25       Impact factor: 5.682

Review 4.  Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.

Authors:  Jiting Wang; Jun Li; Guiju Tang; Yuan Tian; Song Su; Yaling Li
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

5.  Predictive Value of Preoperative Serum AFP, CEA, and CA19-9 Levels in Patients with Single Small Hepatocellular Carcinoma: Retrospective Study.

Authors:  Leijuan Gan; Shaohua Ren; Mengran Lang; Guangtao Li; Feng Fang; Lu Chen; Yayue Liu; Ruyu Han; Kangwei Zhu; Tianqiang Song
Journal:  J Hepatocell Carcinoma       Date:  2022-08-13

6.  Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients.

Authors:  Jinren Zhou; Qing Shao; Yunjie Lu; Yu Li; Zibo Xu; Bo Zhou; Qiuyang Chen; Xiangyu Li; Xiaozhang Xu; Yufeng Pan; Zhenhua Deng; Yiming Wang; Yue Yu; Jian Gu
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

7.  Impact of the Stress Status of Employees on the Enterprise Technology Management Cost Through Matter-Element Analysis Under Psychological Health Education.

Authors:  Ximeng Zhang; Fanshen Han; Ming Gao; Lu Liu; Xiaping Wang
Journal:  Front Psychol       Date:  2021-07-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.